Blackston Financial Advisory Group LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Blackston Financial Advisory Group LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 8.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,145 shares of the company’s stock after purchasing an additional 245 shares during the quarter. Blackston Financial Advisory Group LLC’s holdings in Johnson & Johnson were worth $561,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Taylor & Morgan Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after acquiring an additional 57 shares during the last quarter. Circle Wealth Management LLC grew its stake in Johnson & Johnson by 0.5% during the 1st quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock worth $2,007,000 after buying an additional 59 shares during the last quarter. Red Wave Investments LLC grew its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock worth $530,000 after buying an additional 59 shares during the last quarter. Argus Investors Counsel Inc. grew its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after buying an additional 61 shares during the last quarter. Finally, Alta Capital Management LLC grew its stake in Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after buying an additional 61 shares during the last quarter. 68.59% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.1 %

JNJ opened at $177.01 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business has a 50 day simple moving average of $168.35 and a 200-day simple moving average of $171.28. The stock has a market capitalization of $462.79 billion, a P/E ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the firm earned $2.60 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.55%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson declared that its board has authorized a stock repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts recently issued reports on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Sanford C. Bernstein dropped their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Barclays assumed coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $181.33.

Insider Activity at Johnson & Johnson

In related news, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold 212,646 shares of company stock valued at $36,791,022 in the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.